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Summary
 Background There are clinical and pathological factors associated with the clinical course of 
melanoma. These parameters allow us to predict survival times and establish a 
course of treatment.
 Aim The aim of the study was to assess the signiﬁ cance of immunohistochemical mark-
ers in the progression of melanoma, and relate these ﬁ ndings to the inﬂ uence 
of clinical and histological factors on survival time.
 Materials/Methods In this study, archival histological material obtained from 50 melanoma patients 
operated on in the Great Poland Cancer Centre between 1990–1995 was ana-
lysed. Using immunohistochemistry we detected the presence of markers known 
to be important in the diagnosis of melanoma, including: HMB-45, PCNA, Ki-67, 
MMP-2, CD44 and nm23. Following this, univariate logistic regression was per-
formed and clinical, histopathological and immunohistochemical data of statis-
tical signiﬁ cance were correlated with survival time using the Cox nonparamet-
ric proportional hazard regression model.
 Results The results suggested that the most important prognostic factors correlating with sur-
vival time were: the presence of nm23 antigen (p=0.0342) and the thickness of the 
melanoma, as measured by the Breslow method in mm (p=0.0191). According to the 
univariate analysis there were correlations between patient death or survival and the 
histological type, Superﬁ cial Spreading Melanoma Malignum (SSMM) (p=0.0187), 
regional lymphatic metastases (p=0.0030) and positive Ki-67 results (p=0.0282).
 Conclusions Taken together, our results allowed us to conclude (a) that there was a correla-
tion between survival time and nm23 antigen expression and the thickness of 
melanoma, as measured by the Breslow method in mm, (b) that there were cor-
relations between patient survival or death and the histological type of Superﬁ cial 
Spreading Melanoma Malignum, regional lymphatic metastases and positive Ki-67, 
(c) that other parameters (age, gender, anatomical location of the melanoma, 
the presence of ulceration, lymphatic inﬁ ltration, the existence of satellites, and 
positive PCNA and MMP-2) showed no signiﬁ cant inﬂ uence on survival.
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BACKGROUND
There are clinical and pathological factors associ-
ated with the clinical course of melanoma. These 
parameters allow us to predict survival times and 
establish a course of treatment. Clinical parame-
ters include the following: age, gender, and ana-
tomical localisation of the tumour [1]. Typical his-
tological prognostic factors are: the thickness of 
melanoma, measured by the Breslow method in 
mm [2], the status of regional lymph nodes [3], 
the level of invasiveness measured according to 
Clark [2] and the histological type of the melano-
ma [4–8]. Some authors have also reported a cor-
relation between ulceration and vessel invasion 
with tumour invasion level [6]. Also, Clemente 
examined the involvement of lymphocyte inﬁ l-
tration [9]. Many authors regarded lesion thick-
ness and the existence of lymphatic metastases 
to be an independent prognostic factor [3,4,6]. 
The correlation between other factors is still a 
matter of some debate and therefore the search 
for new factors and research in previously un-
explored areas is necessary to improve the re-
sults of treatment and to gain an improved un-
derstanding of melanoma. In this work, despite 
the factors listed below, we examined a group of 
markers introduced to diagnostic of melanoma 
in recent years. Generally these factors fell into 
two groups, the ﬁ rst represented metastasis-as-
sociated factors (MMP-2, CD44 and nm23), the 
second represented proliferation markers – Ki-67 
(MIB1) and PCNA.
The ability of tumour cells to adhere is a crucial 
step in the metastatic process, altering the clin-
ical prognosis of some human tumours such as 
melanoma. The prognostic value of proteolyt-
ic enzymes in melanoma have been studied and 
MMP-2 belongs to this group [10]. Such enzymes 
allow tumour cells, via changes to their adhesive 
properties, to migrate and form remote metas-
tases. Differences in MMP-2 expression between 
primary and metastatic melanomas have been 
demonstrated [10,11]. Increased expression of 
MMP-2 has been shown to correlate with an inva-
sive phenotype. Moreover, signiﬁ cant prognostic 
parameters which correlate with the expression 
of this protein include: the presence of cathepsin 
B and D, gender, lesion location, tumour thick-
ness according to Breslow, the level of invasion 
according to Clark and presence of ulceration 
[12–14]. CD44, a member of the hyaluronan 
binding-proteins family, has been implicated as 
a contributor in tumour progression and metas-
tasis [15,16]. It has been demonstrated , that the 
expression of this glycoprotein on the surface 
of melanoma cells increases its migration abili-
ty, and in consequence, increases its metastatic 
potential [17–19]. It has been suggested that the 
nm23 gene represents a class of metastatic associ-
ated genes [20–22]. The expression of nm23 was 
found to be inversely related to local recurrence, 
the level of invasion and tumour thickness [23], 
but its prognostic role in the case of melanomas 
of the skin is highly controversial owing to differ-
ing results obtained from gene and protein ex-
pression [23,24]. Nevertheless, a potential corre-
lation has been found between nm23 expression 
and the survival of melanoma patients [25,26]. 
The presence of proliferation markers may sug-
gest an inﬂ uence on tumour invasion potential 
[26]. Karbowniczek et al. [27] described a cor-
relation between MIB-1 (Ki-67) expression, the 
area and shape of melanoma cell nuclei, the thick-
ness of the lesion according to Breslow, the level 
according to Clark and the metastatic potential. 
Other authors have emphasized the importance 
of Ki-67, its inﬂ uence on tumour invasion level, 
and its correlation with survival probability [28]. 
Other markers applied in melanoma diagnosis, 
such as HMB-45, do not seem to have any prog-
nostic value.
During the evolution of prognosis in cases of 
melanoma, several markers have been used but 
none of them was powerful alone. Certain prog-
nostic factors, however, correlate highly with the 
biological behaviour of this type of cancer.
AIM
The aim of our study was to assess the signiﬁ cance 
of immunohistochemical markers in melanoma 
progression compared with the inﬂ uence of clin-
ical and histological factors on survival time.
MATERIALS AND METHODS
Clinical, histopathological and immunohis-
tochemical data are presented in Tables 1–3. 
The analysed data represents the cases of 50 pa-
tients operated for melanoma in the Second 
Oncological Surgery Ward of the Great Poland 
Cancer Centre, Poznań. The average age of the 
examined patients was 53.4 years (range 27–83 
years, standard deviation 14.01). The group in-
cluded 34 women (68%) and 16 men (32%). 
Clinical data such as: age, gender, the occur-
rence of tumour spread, anatomical location 
of the tumour and survival time were assessed. 
Reassessment of archived haematoxylin & eosin 
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Characteristic No Percentage
Patient number 50 100%
Mean age, range 53.5 27–83 years
Gender
male 16 32%
female 34 68%
Five year survival 24 48%
Dissemination 23 46%
Site of metastases
lymph node 8 16%
skin 21 42%
internal organs 16 32%
Lesion location
trunk, shoulder girdle, neck or head 25 50%
limbs 25 50%
Extent of ﬁ rst operation
Lymphadenectomy carried out along with tumour excision 21 42%
Tumour excision only 29 58%
Table 1. Clinical characteristics of patients.
Characteristic No Percentage
Histological type
SSMM 42 84%
NMM 8 16%
Thickness according to 
Breslow
0–0.75 9 18%
0.76–1.5 10 20%
1.51–4.0 10 20%
>4.0 21 42%
Level of invasion 
according to Clark
I – –
II 6 12%
III 24 48%
IV 14 28%
V 6 12%
Metastases to lymph nodes 21 42%
Lymphocyte inﬁ ltration 21 42%
Regression symptoms 18 36%
Presence of ulceration 24 48%
Satellites 0 0%
Preexisting naevus 5 10%
Melanin pigment 45 90%
Table 2. Histological characteristics of tumour data.
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stained histopathological specimens was carried 
out and the ﬁ ndings were described in terms of: 
the thickness of melanoma inﬁ ltration in mil-
limeters, as measured by the Breslow method, 
the level of invasion according to Clark, histo-
logical type, the presence of lymphocyte inﬁ l-
tration, regression features, the existence of a 
preexisting naevus, the presence of ulceration, 
the existence of satellites and lymphatic metas-
tases. Lesions located on the trunk, head, neck, 
shoulder girdle, of original focus, were found in 
25 patients (50%) and were located on the limbs 
of 25 patients (50%). Melanoma spread during 
the observation period was noted in 23 patients 
(46%). Metastases were most frequently found 
in the lymph nodes – 21 cases (42%), as well as 
in the internal organs – 16 cases (32%) and the 
skin – 8 cases (16%). With regards to the thick-
ness of lesions, according to Breslow, in the range 
<1mm there were 9 patients (18%); from 1.01 to 
2.0mm – 10 patients (20%); from 2.01 to 4.0mm 
– 10 patients (20%) and >4.0mm – 21 patients 
(42%). Level II invasion according to Clark was 
found in 6 patients (12%), level III in 24 cases 
(48%), level IV in 14 cases (28%) and level V in 
6 patients (12%). In the examined group of pa-
tients, regional lymphatic metastases were found 
in 21 patients (42%) at the beginning of treat-
ment. Superﬁ cial forms of SSMM type melano-
mas were seen in 42 patients (84%), and nod-
ular types in 8 patients (16%). The existence 
of ulceration was found in 24 patients (48%). 
Regression symptoms were found in 18 patients 
(36%). Lymphocyte inﬁ ltration occurred in 21 pa-
tients (42%). The existence of a preexisting nae-
vus was observed in 5 patients (10%). Amelanotic 
type melanomas were present in 10% of the ex-
amined group (5 patients). No satellite changes 
were found in the examined patients.
Immunohistochemical staining was performed-
using the EnVision system (DAKO). Immu-
noreagents used were from the DAKO and 
CHEMICON Corporations. Tests for the expres-
sion of immunohistochemical markers were per-
formed on tissue material derived from forma-
lin-ﬁ xed, parafﬁ n embedded specimens. Sections 
were cut at 4–5 µm, mounted on APES coat-
ed glass slides and incubated for 20 minutes at 
58°C. Sections were de-paraﬁ nized overnight in 
xylene and subsequently rehydrated through 
graded alcohols. Sections were washed in Tris-
buffered-saline for 15’ and incubated in citrate 
buffer (pH=6,0; acid monohydrate 10 mmol/L 
adjusted with 2N sodium hydroxide) in a micro-
wave for 30 minutes at 250 W (microwave treat-
ment applied to CD44, MMP-2 and Ki67 tests). 
The slides were rinsed in TBS for 15 minutes. 
Endogenous peroxidase activity was blocked us-
ing 3% H2O2 for 10 minutes. After rinsing in 
water for 10 minutes and in TBS for 15 min-
utes, sections were incubated with primary anti-
bodies for 60 minutes (HMB45: 1/50 – DAKO 
– Code M 634, PCNA: 1/100 – DAKO – Code 
M 0879, Ki-67: 1/100 – DAKO – Code M 7240, 
CD44: 1/100 – DAKO – Code M 70 82 and MMP-
2: 1/200 – CHEMICON – Code MAB 13405) or 
with polyclonal rabbit antibodies: (nm23: 1/100 
– DAKO – Code A 0096). After rinsing in water 
for 15 minutes and rinsing in TBS, sections were 
incubated with EnVision+™/HRP (Mouse) com-
plex (DAKO – Code: K 4001) or with EnVision™/
HRP (Rabbit) complex (DAKO – Code: K 4003) 
for 30 minutes. The peroxidase reaction was vis-
ualized for all examined markers using 3,3-di-
aminobenzidine as a chromogen. The sections 
were counterstained in Mayer’s haematoxylin, 
dehydrated through a series of graded alcohols, 
cleared in xylene and mounted under coverslips. 
As positive controls, conﬁ rmed melanoma tissue 
was used for HMB45 and Ki-67, breast carcinoma 
material for PCNA and nm23, vesicle cancer was 
used for MMP-2 and lymph node sections were 
used for CD44.
Immunohistochemical factor No Percentage
HMB45 positive 50 100%
PCNA positive 38 76%
nm23 positive 30 60%
MMP-2 positive 23 46%
CD44 positive 34 68%
Ki-67 positive 35 70%
Table 3. Immunohistochemical data.
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Tumours were scored by assessing the site of stain-
ing (nucleus for Ki-67 and PCNA, membrane for 
CD44 and cytoplasm for HMB45, MMP-2 and 
nm23) and the proportion of positive cells. All 
markers were considered as negative (–), when 
no staining or very weak staining in single cancer 
cells (<10%) was found or as positive (+) when 
at least 50% of examined cell structures were at 
least weakly stained or when more than 10% of 
examined cells showed intensive staining.
Statistical analysis was performed using univar-
iate logistic regression. The Shapiro-Wilks and 
Lilliefors test was used, followed by the t-Student 
and c2 square tests, with Yates’ modiﬁ cations, and 
Fisher’s exact test. The Mann–Whitney U-test 
served as the nonparametric method. The statis-
tical signiﬁ cance of analysed factors on patient 
survival or death was assessed. Survival probability 
was estimated by use of the Kaplan-Meier method. 
Subsequently, clinical, histopathological and im-
munohistochemical data of statistical signiﬁ cance 
were correlated with survival time. The statistical 
signiﬁ cance of prognostic factors on survival time 
was assessed by the Cox nonparametric propor-
tional hazard regression model. A p value <0.05 
was considered statistically signiﬁ cant for all pro-
cedures. The statistical analysis was performed us-
ing Statistica for Windows version 6.0.
RESULTS
The average age in the examined group of pa-
tients was 53.4 years (age range 27-83 years, stand-
ard deviation 14.01). The group included 34 wom-
en (68%) and 16 men (32%). 24 patients (48%) 
survived for over 5 years.
The HMB-45 marker reacted positively in 50 cases 
(100%), PCNA in 38 cases (76%), Ki-67 expres-
sion was detected in 35 cases (70%), MMP-2 in 
23 patients (46%), nm23 was positive in 30 pa-
tients (60%) and ﬁ nally, CD44 was observed in 
34 patients (68%).
The median survival time, according to the 
Kaplan-Meier analysis, was 89 months – lower 
quartile (25th percentile) 36.46 months. The 
curve of survival is presented in Figure 1.
The statistical signiﬁ cance of the examined 
prognostic factors was assessed using the Cox 
proportional hazards regression model of sur-
vival.
Due to the lack of satellite changes and 100% pos-
itive reaction to HMB-45 antigen, these indica-
tors were excluded from further statistical anal-
ysis in the examined group of patients.
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Figure 1. Graph of survival times vs. the cumulative proportion surviving, according to the Kaplan-Meier method.
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The following parameters were analysed: age, gen-
der, lesion location, the extent of surgery (lym-
phadenectomy carried out along with tumour 
excision), the depth of invasion in mm accord-
ing to Breslow, the level of invasion according to 
Clark, the existence of lymphatic metastases, his-
tological type of SSMM, regional lymph metas-
tases, ulceration, regression factors, the presence 
of a preexisting naevus, lymphocytic tumour in-
ﬁ ltration, the presence of melanin, expression 
of PCNA, Ki-67, metalloproteinase 2 (MMP-2), 
CD44 glycoprotein and nm23 diphosphate nucl-
eoside kinase. The statistical signiﬁ cance of ana-
lysed factors on patient survival or death was as-
sessed. The results of this analysis are presented 
in Table 4. The statistical signiﬁ cance of prog-
nostic factors on survival time was assessed by 
the Cox nonparametric proportional hazard re-
gression model. These ﬁ nal results are present-
ed in Table 5.
There were correlations between patient sur-
vival or death and the thickness of the melano-
ma, as measured by the Breslow method in 
mm (p=0.0188), histological type of Superﬁ cial 
Spreading Melanoma Malignum (SSMM) 
Variable 0 1 P
Age 50.89±13.97 55.06±14.03 ns
Gender
K  n=14 73.7%  n=20 64.5%
ns
M  n=5 26.3%  n=11 35.5%
Limb lesion location  12 63.1%  13 41.9% ns
SSMM  13 68.4%  29 93.5% p=0.0187*
Breslow <1.0 mm  1 5.2%  8 25.8%
p=0.0183*
1.01–2 mm  3 15.8%  7 22.6%
2.01–4 mm  3 15.8%  7 22.6%
>4 mm  12 63.2%  9 29.0%
Clark I level
ns
II level  1 5.3%  5 16.1%
III level  8 42.1%  16 51.6%
IV level  8 42.1%  6 19.4%
V level  2 10.5%  4 12.9%
Regression factors  5 26.3%  13 41.9% ns
Lymphocyte tumour inﬁ ltration  9 47.4%  12 38.7% ns
Preexisting naevus  3 15.8%  2 6.4% ns
Melanin  15 78.9%  30 96.8% ns
Ulceration  13 68.4%  11 35.5% ns
Regional lymph metastases  13 68.4%  8 25.8% p=0.0037*
Elective lymphadenectomy  9 47.4%  12 38.7% ns
HMB 45  19 100.0%  31 100.0% ns
PCNA  15 78.9%  23 74.2% ns
Nm23  16 84.2%  14 45.2% p=0.0107*
MMP-2  8 42.1%  15 48.4% ns
CD44  12 63.2%  22 70.9% ns
Ki-67  19 61.3%  16 84.2% p=0.0282*
Table 4. The statistical signiﬁ cance of analysed factors, as assessed by univariate logistic regression.
* p<0.05; ns – not signiﬁ cant.
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(p=0.0187), regional lymphatic metastases 
(p=0.0030), positive Ki-67 (p=0.0282) and nm23 
antigen expression (p=0.0107).
The expression of nm23 diphosphate nucleo-
side kinase (p=0.0342) and the thickness of the 
melanoma, as measured by the Breslow method 
in mm (p=0.0191), also showed a statistical cor-
relation with survival time.
Analyses carried out on the following selected pa-
rameters: age, gender, lesion location, whether 
or not lymphadenectomy was carried out along 
with tumour excision, positive reaction to PCNA, 
metalloproteinase 2 (MMP-2), the expression of 
CD44 glycoprotein, the presence of a preexisting 
naevus, the level of invasion according to Clark, 
the presence of ulceration, regression symptoms, 
lymphocyte inﬁ ltration and expression of mela-
nin showed no statistically signiﬁ cant inﬂ uence 
on patient survival.
DISCUSSION
An important element in planning treatment is 
to determine which groups of patients are at in-
creased risk of disease progression. Correlations 
between the investigated factors in this study al-
lowed us to determine such a group of persons.
The prognostic value of molecular markers
A prognostic factor in the examined group turned 
out to be a positive reaction for the presence of 
nm23 diphosphate nucleoside kinase. Its impor-
tance has been emphasized in the literature by 
some authors, while others have not observed 
such a correlation, such that the prognostic 
value of nm23 expression remains uncertain. 
Betke et al. performed an assessment for the 
presence of nm23 protein in benign naevi, ma-
lignant melanomas and melanoma metastases 
to lymph nodes and internal organs [21] and 
found that reduced nm23 expression was relat-
ed to a strong correlation with patient survival 
time and metastases (p=0.0003). Similar corre-
lations for nm23 expression in melanoma were 
conﬁ rmed by Florenes et al. [22] and Lee et al. 
[20] while such authors as Van den Oord et al. 
[26], Saitoh et al. [23] and Holmes et al. [24] 
observed no correlation between nm23 expres-
sion in melanoma and survival time or metasta-
sis formation. Many authors have studied nm23 
expression in other human cancers. The corre-
lation between reduced levels of nm23 protein 
and survival time has been described in ductal 
breast cancer with regional lymphatic metastas-
es [29]. In colon cancer the correlation between 
reduced nm23 levels and the occurrence of me-
tastases in the liver was shown, but not related to 
the condition of regional lymphatic nodes [30]. 
In our group of patients the detection of nm23 
expression in melanoma cells correlated with a 
prolonged survival time.
Some authors have emphasized the importance 
of Ki67 in the differentiation of melanoma cells. 
Its proliferative effects and indirect inﬂ uence on 
tumour invasion level, however, meant that they 
could not always conﬁ rm correlations with survival 
rate [27,28,31]. Karbowniczek et al. [27] described 
an increased median nuclear diameter with pos-
itive results for Ki67 and a correlation with the 
depth of invasion, in mm, according to Breslow 
and the level of metastatic potential according to 
Clark. Talve et al. [28] stressed the importance of 
proliferative parameters such as: Ki67 and mitotic 
index, but did not show an inﬂ uence on survival 
Statistical survival analysis Depended variable: survival – (months) Χ2=28.18 ; df=6 ; p=0.00009 (p<0.05) 
Prognostic factor Beta Statistical error Exponent beta (relative risk) Wald statistic p
Lymph node metastases 0.82 0.56 2.27 2.14 ns
Breslow thickness 0.71 0.30 2.03 5.49 p=0.0190*
SSMM type –1.56 0.92 0.21 2.86 ns
nm23 2.11 0.99 8.24 4.48 p=0.0342*
Ki-67 0.07 1.09 1.07 0.004 ns
Table 5. Statistically signiﬁ cant factors associated with survival time, as assessed by the Cox nonparametric proportional hazard regression 
model.
* p<0.05; ns – not signiﬁ cant.
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rate. Rudolph et al. [31] demonstrated the value 
of Ki67 in the diagnosis and differentiation of be-
nign melanocytic changes and melanoma.
In our study Ki67 antigen was detected in the nu-
clear area of primary melanoma tumour cells, in 
35 (70%) melanoma cases, and showed a statisti-
cal correlation with the probability of survival or 
death. Possibly, expression levels for Ki67 would 
be helpful in the determination of the aggres-
siveness and metastatic potential of melanomas. 
We demonstrated no correlation between Ki67 
expression and patient survival time.
Immunohistochemical studies conﬁ rmed the di-
agnostic value of the HMB45 marker but showed 
that it has no prognostic value because of its near-
ly 100% speciﬁ city for melanoma. The inﬂ uence 
of PCNA, CD44, MMP-2 on the probability of sur-
vival or death was not determined.
Analysis of histopathological factors
Most studies have indicated that the single best 
predictive attribute for clinical outcome for a 
given patient is the depth of tumour invasion 
(Breslow), and that this is the most powerful inde-
pendent prognostic factor [2,32]. It has become 
the gold standard for stratifying patients accord-
ing to the risk of metastatic disease. These studies 
showed that, as we expected, tumour thickness 
in our patients was an accurate indicator for the 
biological behaviour of melanoma. In the ana-
lysed material, the depth of invasion, in mm ac-
cording to Breslow, showed statistically signiﬁ -
cant inﬂ uence on patient survival, but the level 
of invasion according to Clark showed no inﬂ u-
ence on survival.
In the examined group of patients, we observed 
improved prognosis for patients with the SSMM 
histological type of melanoma. A similar cor-
relation has also been recognized by other au-
thors [1,3,6].
The existence of lymphatic metastases is one of 
the most predictive negative factors affecting 
the clinical course for patients with cutaneous 
melanoma [33]. In our material, univariate anal-
yses disclosed that this factor had an independ-
ent negative impact on patients’ risk of death. 
We could not conﬁ rm an inﬂ uence on overall 
patient survival.
No other prognostic factors, such as the pres-
ence of ulceration, lymphatic inﬁ ltration, the 
existence of satellites or preexisting melanocytic 
naevi could be demonstrated by statistical corre-
lation in our studies.
Analysis of clinical parameters
Our studies showed that 25% of patients died 
during a period of 36.46 months and that 50% 
lived longer than 89 months. None of the clini-
cal parameters associated with survival time dis-
played signiﬁ cant inﬂ uence on survival, in the 
studied group of patients.
The markers analysed in this article, have been 
previously shown to be useful prognostic factors, 
or potential candidates, for determining progno-
sis in the context of melanoma disease progres-
sion. Most of these markers correlated with clinical 
or histological factors. Clinical prognostic signiﬁ -
cance, however, was demonstrated mostly in deep-
ly invasive or metastatic stages of tumour progres-
sion, meaning that the predictive value for the 
clinical outcome was valid only for that subgroup 
of patients. It was found that no single histologi-
cal, immunohistochemical, serological or molec-
ular marker can provide a precise predictive value 
for aggressive behavior in melanoma patients, re-
gardless of clinical stage or tumour size. However, 
combinations of markers with histological param-
eters would help to identify patients at high risk of 
developing metastases and who would thus bene-
ﬁ t from more aggressive treatment.
CONCLUSION
We concluded that: (a) the expression of nm23 
diphosphate nucleoside kinase showed a statistical 
correlation with survival time, meaning improved 
prognosis for patients with skin melanoma, and 
(b) that a second signiﬁ cant prognostic factor 
in this analysis was the thickness of the melano-
ma, as measured by the Breslow method in mm, 
and (c) that, according to a univariate analysis, 
there were correlations between patient survival 
or death and the histological type of Superﬁ cial 
Spreading Melanoma Malignum, regional lym-
phatic metastases and positive Ki-67. (iv) Other 
parameters displayed no signiﬁ cant inﬂ uence on 
survival time in the examined group.
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